A.XuZ.Karam SarkisD.TouquiL
& Sobgui, C
Tejaswi Kompala, Senior Director, Clinical Strategy, Teladoc Health and Robert Hsu, Director, Clinical Strategy, Teladoc Health The early stages of any new, clinically impactful drug put pressure on benefit leaders
Hin nay, nhiu nh sn xut kt hp thm cc cht in gii vo BCAA/EAA
Biomarker and genetic context help determine which approach aligns best with your specific health profile and needs
Additionally, it must be noted that an individual biomarker, for example, sKlotho, inherently has some limitations for accurate diagnosis and monitoring progression in CKD without the combination of a set of other biomarkers because a single indicator lacks sufficient performance and efficiency to reflect the complexity of the mechanisms underlying CKD pathogenesis and development